

[PD1-48] [10/19/2001 (Fri) 14:00 – 17:00 / Hall D]

Inhibition of prostaglandin E₂ production by hydroxychalcone derivatives and the mechanism of action

Jung SangHoon, Shin KukHyun, Lim SoonSung, Ji Jun, Kim YongPil¹, Ban HyunSeung¹, Ohuchi Kazuo¹.

Natural Products Research Institute, Seoul National University, ¹ Graduate School of Pharmaceutical Sciences, Tohoku University, Japan

Effects of fifteen chalcone derivatives synthesized on prostaglandin E₂ production in rat peritoneal macrophages stimulated by 12-O-tetradecanoylphorbol-13-acetate (TPA), were examined to clarify the structure-activity relationship. Among chalcone derivatives tested, 2',4-dihydroxy-4'-methoxychalcone (compound 3), 2',4-dihydroxy-6'-methoxychalcone (compound 8) and 2'-hydroxy-4'-methoxychalcone (compound 9) were found to suppress significantly prostaglandin E₂ production, even at the concentration as low as 3 μM. Cyclooxygenase (COX)-1 isolated from sheep seminal vesicle was slightly inhibited by compound 9, although it showed no inhibition of COX-2 isolated from sheep placenta. At concentrations to inhibit prostaglandin E₂ production, compound 9 showed no effect on the release of radioactivity from [³H]arachidonic acid-labeled macrophages stimulated by TPA. Western blot analysis revealed that the induction of COX-2 protein by TPA was inhibited by these three compounds in parallel with the inhibition of prostaglandin E₂ production. These findings suggest that the inhibition of prostaglandin E₂ production by these chalcone derivatives is due to the inhibition of TPA-induced COX-2 protein expression and 2-hydroxy, 4- or 6-methoxy and 4'-hydroxy or 4'-hydrogen groups are required for the expression of the inhibitory activity of prostaglandin E₂ production.

[PD1-49] [10/19/2001 (Fri) 14:00 – 17:00 / Hall D]

Novel Platinum(IV) compound, K101, having octahedral structure as Anticancer agent I – Synthesis and Evaluation of Anticancer activity

Kwon Young-Ee, Lee Hwa Jung⁰, Hur Jin Haeng, Kim Gyung-Ok, Park Min Su, Lee Sang Eun

New Drug R&D Institute, STC Life Science Center

Novel Pt(IV) compound, trans,cis-[Pt(acetato)₂Cl₂(1,4-butanediamine)] (K101) was synthesized for the purpose of development as new anticancer drug. The octahedral structure of trans,cis-[Pt(acetato)₂Cl₂(1,4-butanediamine)] was determined by X-ray crystal diffraction method. Anticancer activity was examined using murine and human 12 cancer cell lines. Among them, K101 has shown excellent anticancer activity in human colon and breast cancer cell line relative to cisplatin in vitro. In IC₅₀ values, K101 is 1.95, 1.23 μmol/ml and cisplatin is 7.89, 14.67 μmol/ml in HCT116, HCT15 cell lines, K101 is 1.86, 1.25, 2.89 μmol/ml and cisplatin is 10.33, 12.23, 17.51 μmol/ml in SK-BR3, MCF7, MDA-MB231, respectively. In vivo activity against mouse B16 melanoma, antitumor activity of K101 is similar to cisplatin.

[PD1-50] [10/19/2001 (Fri) 14:00 – 17:00 / Hall D]

Selective cytotoxicity of a new platinum(II) complex on human ovarian cancer cell-lines and normal kidney cells

Rho Young-Soo, Jung Jee-Chang

College of Pharmacy and School of Medicine, Kyung Hee University, Seoul 130-701, Korea

Cisplatin is important antineoplastic agent, but dose-limiting nephrotoxicity prevents potential efficacy. There is interest in developing new platinum agents that have less toxicity. We have synthesized a novel platinum (II) coordination complex containing cis-1,2-diaminocyclohexane as a carrier ligand, and glycolic acid as a leaving group. In this study, new platinum (II) complex compound [Pt(II)(cis-DACH)(GA)] was evaluated for cytotoxicity on cancer cell-lines and normal kidney cells. The new platinum complex has demonstrated high efficacy in the cytotoxicity against human ovarian adenocarcinoma cell lines (SKOV-3/NIH OVCAR-3). The cytotoxicity of this compound against rabbit proximal renal tubular cells and human renal cortical tissues was determined by MTT assay, the [3H]-thymidine uptake and glucose consumption test, and found to be quite less than those of cisplatin. Based on these results, this novel platinum compound appears to be a valuable lead compound with high efficacy and low nephrotoxicity.

[PD1-51] [10/19/2001 (Fri) 14:00 – 17:00 / Hall D]

Synthesis and Analgesic-antiinflammatory Activity of Cinmetacin Amides

Im ChaeUK, Jun SangChul⁰, Hong YongKi, Yim ChulBu

Division of Medicinal Chemistry, College of Pharmacy, Chung-ang University

Five cinmetacin amides as potential nonsteroidal analgesic and antiinflammatory compounds were prepared and their analgesic-antiinflammatory activity was compared with cinmetacin. Cinmetacin and hydroxysuccinimide were reacted with dicyclohexyl carbodiimide to give cinmetacin active ester (4), which was treated with amines to yield cinmetacin amides (5-9). Compounds (5) and (9) showed stronger analgesic activity than cinmetacin, and compounds (5), (6), (9) showed comparable antiinflammatory activity to cinmetacin.

[PD1-52] [10/19/2001 (Fri) 14:00 – 17:00 / Hall D]

Total synthesis of (+)-Spectraline

Oh ChangYoung, Kim YongHyun, Lee YiuSeok, Ham WonHun

College of Pharmacy, Sungkyunkwan University

Functionalized piperidines are very important heterocycles because of their presence in numerous alkaloids, pharmaceuticals, and synthetic intermediates. Recently, we have reported diastereoselective palladium(0)-catalyzed oxazoline formation reaction from the acyclic allylic and homoallylic benzamide (Tetrahedron Lett. 1998, 39, 8129, J. Org. Chem. 1999, 64, 9450). We envisioned that this method could be utilized to set the vicinal amino alcohol stereochemistry of (+)-spectraline. Also, we envisaged that hydrogenolysis of the oxazoline generated amino group, which condensed intramolecularly with the carbonyl group spontaneously to provide piperidine, which was in situ hydrogenated with hydrogen coming from the least hindered surface to provide the piperidine. The key steps in our strategy are diastereoselective oxazoline formation reaction catalyzed by Pd(0) and piperidine formation by hydrogenolysis of oxazoline using Pearlman's catalyst.

[PD1-53] [10/19/2001 (Fri) 14:00 – 17:00 / Hall D]

Total Syntheses of Spingofungin F

Oh ChangYoung, Ham WonHun